A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

NCT06315491 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-resistant Ovarian Cancer
Refractory Ovarian Carcinoma

Interventions

DRUG: CBX-12

Sponsor

Cybrexa Therapeutics